{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:05:57Z","timestamp":1793023557459,"version":"4.5.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.21869","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T12:02:36Z","timestamp":1611230556000},"page":"e2021869","source":"Crossref","is-referenced-by-count":300,"title":["Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival"],"prefix":"10.1001","volume":"4","author":[{"given":"Shaan","family":"Dudani","sequence":"first","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Connor","family":"Wells","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Loo","family":"Gan","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[{"name":"Department of Oncology,Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Pavia, Pavia, Italy"},{"name":"Now with Department of Oncology, University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fraccon","sequence":"additional","affiliation":[{"name":"CDC Pererzoli, Peschiera del Garda, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Pasini","sequence":"additional","affiliation":[{"name":"Oncologia Medica Ospedale Santa Maria della Misericordia, Rovigo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Lyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Hansen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"Bjarnason","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Sunnybrook Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Beuselinck","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yuasa","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Kroeger","sequence":"additional","affiliation":[{"name":"Department of Urology, University Medicine Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Neil","family":"Reaume","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Canil","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y. C.","family":"Heng","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"issue":"10","key":"zoi200737r1","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia.","volume":"37","author":"Srigley","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"zoi200737r2","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1200\/JCO.2005.07.055","article-title":"Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience.","volume":"23","author":"Patard","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi200737r3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma.","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"issue":"7456","key":"zoi200737r4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma.","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"2","key":"zoi200737r5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma.","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi200737r6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma.","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"zoi200737r7","first-page":"409","article-title":"Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.","volume":"15","author":"Malouf","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"zoi200737r8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.juro.2009.12.035","article-title":"Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.","volume":"183","author":"Leibovich","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"zoi200737r9","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.juro.2009.07.019","article-title":"Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma.","volume":"182","author":"Teloken","year":"2009","journal-title":"J Urol"},{"issue":"5","key":"zoi200737r10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cam4.1048","article-title":"Characterizing the outcomes of metastatic papillary renal cell carcinoma.","volume":"6","author":"Connor Wells","year":"2017","journal-title":"Cancer Med"},{"issue":"1","key":"zoi200737r11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/KCA-160002","article-title":"Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC).","volume":"1","author":"Yip","year":"2017","journal-title":"Kidney Cancer"},{"issue":"4","key":"zoi200737r12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"zoi200737r13","doi-asserted-by":"publisher","first-page":"661.e7","DOI":"10.1016\/j.urolonc.2017.06.060","article-title":"Metastatic renal cell carcinoma: Patterns and predictors of metastases\u2014a contemporary population-based series.","volume":"35","author":"Chandrasekar","year":"2017","journal-title":"Urol Oncol"},{"issue":"4","key":"zoi200737r14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151662","article-title":"Clinical impact of pancreatic metastases from renal cell carcinoma: a multicenter retrospective analysis.","volume":"11","author":"Grassi","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"zoi200737r15","doi-asserted-by":"publisher","first-page":"167.e17","DOI":"10.1016\/j.urolonc.2015.10.015","article-title":"Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.","volume":"34","author":"Gravis","year":"2016","journal-title":"Urol Oncol"},{"issue":"4","key":"zoi200737r16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ajur.2016.08.006","article-title":"Metastasis in renal cell carcinoma: biology and implications for therapy.","volume":"3","author":"Gong","year":"2016","journal-title":"Asian J Urol"},{"issue":"4","key":"zoi200737r17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"issue":"34","key":"zoi200737r18","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"14","key":"zoi200737r19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi200737r20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"10189","key":"zoi200737r21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"zoi200737r22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejca.2016.08.004","article-title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.","volume":"69","author":"Escudier","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi200737r23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi200737r24","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1016\/j.clgc.2019.03.018","article-title":"Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes.","volume":"17","author":"Ged","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"zoi200737r25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bju.13185","article-title":"Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.","volume":"117","author":"Kalra","year":"2016","journal-title":"BJU Int"},{"issue":"3","key":"zoi200737r26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/thy.2014.0498","article-title":"Survival after renal cell carcinoma metastasis to the thyroid: single center experience and systematic review of the literature.","volume":"25","author":"Beutner","year":"2015","journal-title":"Thyroid"},{"issue":"3","key":"zoi200737r27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal.","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"issue":"7","key":"zoi200737r28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134564","article-title":"Pancreatic tropism of metastatic renal cell carcinoma.","volume":"5","author":"Singla","year":"2020","journal-title":"JCI Insight"},{"issue":"11","key":"zoi200737r29","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"zoi200737r30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.euf.2017.12.007","article-title":"The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort.","volume":"5","author":"Sun","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"1","key":"zoi200737r31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF02524349","article-title":"Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.","volume":"11","author":"Beck","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"zoi200737r32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.2531","article-title":"Non-clear cell renal cell carcinomas: from shadow to light.","author":"Albiges","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2775361\/dudani_2021_oi_200737_1610558724.4577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T12:02:38Z","timestamp":1611230558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2775361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.21869","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]}}}